New approaches to the treatment of Ewing Sarcoma are urgently required to find better, kinder and safer options for patients.
Ewing sarcoma is driven by a key genetic mutation (EWSR1-FLI1) which, though well recognised, is notoriously difficult to target for treatment. Researchers at the University of Birmingham are instead looking to target EWS-FLI1 indirectly, focusing on a process known as ‘replication stress’. This is triggered when EWSR1-FLI1 causes cells to rapidly multiply, leading to DNA damage. It must be carefully managed by various pathways and processes within the cell (referred to as the ‘replication stress response’), to ensure that the Ewing sarcoma cells survive.
Replication stress therefore represents a key vulnerability and potential target for treatment as, if it remains unchecked, the Ewing sarcoma cells will not survive.
What are the aims of this research project?
Led by Professor Clare Davies and Dr Susanne Gatz, this project will take forwards this knowledge of replication stress and apply it to a particular protein, PRMT5, which is a known drug target for several other cancers, including breast cancer, brain cancer and leukaemia. They believe that PRMT5 is closely involved in controlling the amount of replication stress induced by EWSR1-FLI1 in Ewing sarcoma cells.
Their research therefore aims to further investigate the link between PRMT5 and EWSR1-FLI1, exploring how they might work together to drive the survival of Ewing sarcoma cells and how this could be blocked using drugs known as ‘inhibitors’ of PRMT5. The researchers will seek to identify possible markers which could indicate which Ewing sarcoma patients are likely to respond to these drugs and will compare the levels and activity of PRMT5 in Ewing sarcoma and other (healthy and breast cancer) tissues.
Furthermore, this research will also explore whether combining PRMT5 inhibitors with other drugs also known to target aspects of the replication stress response could lead to a more effective treatment response.
How could this project improve treatment options for Ewing sarcoma patients?
Since EWSR1-FLI1 is very difficult
to target, establishing a link with the more easily targeted PRMT5 could represent an exciting potential avenue for treatment. Indeed,
several pharmaceutical companies currently have PRMT5 inhibitors at clinical
trial stage to treat adult cancers. If successful, this research could
represent a significant and vital step towards translation
in Ewing sarcoma, leading to a much deeper understanding of its underlying
biology and addressing the crucial need for a more targeted, more effective
treatment option with fewer toxic side effects.
This is one of four pioneering projects funded as part of a groundbreaking £800,000 joint investment into Ewing sarcoma research, made possible thanks to a collaboration between the Bone Cancer Research Trust, CCLG - The Children and Young People's Cancer Association, the Ewing's Sarcoma Research Trust and Great Ormond Street Hospital Charity.
Sponsor Our Research Into Ewing Sarcoma